Login to Your Account



Vical Licenses CMV Vaccine to Astellas for Potential $130M+

By Tom Wall


Monday, July 18, 2011
San Diego-based Vical Inc. signed a potential $130 million-plus license agreement with Astellas Pharma Inc., of Tokyo, for worldwide development and commercialization of Vical's TransVax vaccine for cytomegalovirus (CMV) reactivation in hematopoietic stem cell transplant and solid organ transplant recipients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription